Neuroscience and Behavioral Physiology

, Volume 41, Issue 9, pp 899–905 | Cite as

Chronic Fatigue and Approaches to Its Treatment

  • E. S. Akarachkova


asthenia chronic fatigue diagnosis treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. S. Akarachkova, “Use of ‘Magne-B6’ in wide therapeutic practice,” Trudnyi Patsient, 5, 48–54 (2007).Google Scholar
  2. 2.
    E. S. Akarachkova, “Clinical signs of maladaptation and magnesium deficiency in women aged over 40 years,” in: Healthy Woman after 40 Years: Proc. Sci. Appl. Conf. of Gynecologists, Moscow Medical Academy, May 29–30, 2008 [in Russian], Moscow (2008).Google Scholar
  3. 3.
    E. S. Akarachkova, Asthenia: Characteristics and Contemporary Treatment Agents [in Russian], Novaya Apteka (2008).Google Scholar
  4. 4.
    E. S. Akarachkova, M. Yu. Drobizhev, O. V. Vorobiova, and E. A. Makukh, “Nonspecific pain and depression in neurology,” Zh. Nevrol. Psikhiat., No. 12, 4–10 (2008).Google Scholar
  5. 5.
    E. S. Akarachkova, M. Yu. Drobizhev, and E. A. Makukh, “Asthenia and depression in neurological practice,” Lech. Nerv. Bolezn., 3, No. 25, 35–41 (2008).Google Scholar
  6. 6.
    E. S. Akarachkova, “Calcium channel blockers in neurological practice,” Vrach, No. 9, 35–39 (2009).Google Scholar
  7. 7.
    O. V. Vorobiova and E. S. Akarachkova, “Magne B6: experience of five years of clinical use in neurological and therapeutic practice,” Farmateka, 20, 734–80 (2008).Google Scholar
  8. 8.
    O. A. Gromova, Magnesium and Pyridoxine: A Knowledge Base [in Russian], Moscow (2006).Google Scholar
  9. 9.
    I. V. Damulin, “Moderate cognitive disorders: some pathogenetic, clinical, and therapeutic aspects,” Consilium Medicum, No. 2, 19–24 (2008).Google Scholar
  10. 10.
    V. A. Doskin, N. A. Lavrentiev, M. P. Miroshnikov, and V. B. Sharai, 1 MMI (1973).Google Scholar
  11. 11.
    R. Murray, D. Grenner, and V. Rodwell, Human Biochemistry [Russian translation], Mir, Moscow (1993), Vol. 2.Google Scholar
  12. 12.
    Pathophysiology. A Course of Lectures: A Textbook [in Russian], Moscow (1995).Google Scholar
  13. 13.
    S. B. Shvarkov and E. S. Akarachkova, “Correction of energy and electrolyte balance with magnesium formulations and pyridoxine in neurological diseases,” Med. Tekhnol., 31 (2007).Google Scholar
  14. 14.
    S. Ax, V. H. Gregg, and D. Jones, “Chronic fatigue syndrome: sufferers’ evaluation of medical support,” J. Roy. Soc. Med., 90, 250–254 (1997).PubMedGoogle Scholar
  15. 15.
    H. Aydin, O. Deyneli, D. Yavuz, et al., “Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women,” Biol. Trace Elem. Res., 133, No. 2, 136–143 (2010).PubMedCrossRefGoogle Scholar
  16. 16.
    M. Barbagallo, M. Belvedere, and L. J. Dominguez, “Magnesium homeostasis and aging,” Magnes. Res., 22, No. 4, 235–246 (2009).PubMedGoogle Scholar
  17. 17.
    R. Day, W. Liauw, et al., “A double-blind, placebo-controlled study of the short-term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenopausal women,” BMC Res. Not., 3, 180 (2010).CrossRefGoogle Scholar
  18. 18.
    G. A. Eby and K. L. Eby, “Magnesium for treatment-resistant depression: a review and hypothesis,” Med. Hypothes, 74, No. 4, 649–660 (2010).CrossRefGoogle Scholar
  19. 19.
    K. Fukuda, S. E. Straus, I. Hickie, et al., “The chronic fatigue syndrome: a comprehensive approach to its definition and study,” Ann. Int. Med., 121, 953–959 (1994).PubMedGoogle Scholar
  20. 20.
    L. S. Hadjistavri, P. A. Sarafidis, P. I. Georgianos, et al., “Beneficial effects of oral magnesium supplementation on insulin sensitivity and serum lipid profile,” Med. Sci. Monit., 16, No. 6, 307–312 (2010).Google Scholar
  21. 21.
    F. N. Jacko, S. Overland, R. Stewart, et al., “Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study,” New Zealand J. Psychiat., 43, No. 1, 45–52 (2009).CrossRefGoogle Scholar
  22. 22.
    R. Jorgensen, “Chronic fatigue: an evolutionary concept analysis,” J. Adv. Nurs., 63, No. 2, 199–207 (2008).PubMedCrossRefGoogle Scholar
  23. 23.
    R. J. Lane, B. A. Soteriou, H. Zhang, and L. C. Archard, “Enterovirus related metabolic myopathy: a postviral fatigue syndrome,” J. Neurol. Neurosurg. Psychiat., 74, No. 10, 1382–1386 (2003).PubMedCrossRefGoogle Scholar
  24. 24.
    M. Nechifor, “Interactions between magnesium and psychotropic drugs,” Magnes. Res., 21, No. 2, 97–100 (2008).PubMedGoogle Scholar
  25. 25.
    M. Nechifor, “Magnesium in major depression,” Magnes. Res., 22, No. 3, 163–166 (2009).Google Scholar
  26. 26.
    R. Nisenbaum, J. Jones, E. Unger, et al., “A population-based study of the clinical course of chronic fatigue syndrome,” Health Qualit. Life Outcomes, No. 1, 49 (2003).Google Scholar
  27. 27.
    R. Pokan, P. Hofmann, S. P. von Duvillard, et al., “Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients,” Br. J. Sports Med., 40, No. 9, 773–778 (2006).PubMedCrossRefGoogle Scholar
  28. 28.
    J. B. Prins, G. Bleijenberg, E. Klein Rouweler, et al., “Doctor-patient relationship in primary care of chronic fatigue syndrome: perspective of the doctor and the patient,” J. CFS, 7, 3–15 (2000).Google Scholar
  29. 29.
    L. Solomon, R. Nisenbaum, M. Reyes, et al., “Functional status of persons with chronic fatigue syndrome in the Wichita, Kansas, population,” Health Qualit. Life Outcomes, No. 1, 48 (2003).Google Scholar
  30. 30.
    A. A. Spasov, I. N. Iezhitsa, M. V. Kharitonova, and M. S. Kravchenko, “Depression-like and anxiety-related behaviour of rats fed with magnesium-deficient diet,” Zh. Vyssh. Nerv. Deyat., 58, No. 4, 476–485 (2008).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2011

Authors and Affiliations

  • E. S. Akarachkova
    • 1
  1. 1.MoscowRussia

Personalised recommendations